Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data.

OBJECTIVE To evaluate the relationship between serum cholesterol level and all-cause, coronary heart disease (CHD), and non-CHD mortality as a function of age. METHODS The data source was the biennial examination data from 1948 through 1980 for the 5209 men and women enrolled in the Framingham Heart Study. Age-specific analyses by the Cox proportional hazards regression model were performed of survival subsequent to ages 40, 50, 60, 70, and 80 years for all subjects enrolled and alive at each of the stated ages. Complementary models were studied that used high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or total cholesterol level as predictors of survival subsequent to the examination at which lipoprotein subfractions were determined (1968) through 1973). RESULTS The relationship between total cholesterol level and all-cause mortality was positive (ie, higher cholesterol level associated with higher mortality) at age 40 years, negative at age 80 years, and negligible at ages 50 to 70 years. The relationship with CHD mortality was significantly positive at ages 40, 50, and 60 years but attenuated with age until the relationship was positive, but not significant, at age 70 years and negative, but not significant, at age 80 years. Results for the relationship between low-density lipoprotein cholesterol and high-density lipoprotein cholesterol and mortality help explain these findings. Non-CHD mortality was significantly negatively related to cholesterol level for ages 50 years and above. The negative results in the oldest age group for all-cause and CHD morality appeared to be due to a negative relationship with low-density lipoprotein cholesterol levels rather than the protective effect of high high-density lipoprotein cholesterol levels. Similar results from several modified analyses make low cholesterol level due to severe illness an unlikely explanation for our results. CONCLUSIONS Physicians should be cautious about initiating cholesterol-lowering treatment in men and women above 65 to 70 years of age. Only randomized clinical trials in older people can settle the debate over the efficacy and cost-effectiveness of lipid-lowering interventions for reducing mortality and morbidity in this population.

[1]  R. Kronmal,et al.  Beneficial Six-Year Outcome of Smoking Cessation in Older Men and Women with Coronary Artery , 1989 .

[2]  W. Ettinger,et al.  Characteristics and Outcomes of Hospitalized Older Patients Who Develop Hypocholesterolemia , 1991, Journal of the American Geriatrics Society.

[3]  S B Hulley,et al.  Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. , 1986, American heart journal.

[4]  M. Marmot,et al.  Plasma cholesterol concentration and mortality. The Whitehall Study. , 1992, JAMA.

[5]  B. Rifkind,et al.  The value of lowering cholesterol after myocardial infarction. , 1990, The New England journal of medicine.

[6]  Daniel Steinberg,et al.  Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.

[7]  R. Hiatt,et al.  Serum cholesterol and the incidence of cancer in a large cohort. , 1986, Journal of chronic diseases.

[8]  W. Kannel,et al.  Proportional Hazards Analysis of Risk Factors for Coronary Heart Disease in Individuals Aged 65 or Older , 1988, Journal of the American Geriatrics Society.

[9]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[10]  T. Manolio,et al.  Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. , 1992, Annals of epidemiology.

[11]  W. Hazzard.  Dyslipoproteinemia in the elderly. Should it be treated? , 1992, Clinics in geriatric medicine.

[12]  D. Rudman,et al.  Antecedents of Death in the Men of a Veterans Administration Nursing Home , 1987, Journal of the American Geriatrics Society.

[13]  D. Cox.  Regression Models and Life-Tables , 1972 .

[14]  V. Salomaa,et al.  Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. , 1991, JAMA.

[15]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[16]  I. Holme,et al.  An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. , 1990, Circulation.

[17]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[18]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[19]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[20]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[21]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.

[22]  A. Gotto,et al.  The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute , 1990 .

[23]  W. Browner,et al.  Childhood cholesterol screening: contraindicated. , 1992, JAMA.

[24]  R. Kronmal,et al.  Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. , 1988, The New England journal of medicine.

[25]  Estrogen and coronary heart disease in women. , 1991 .

[26]  U. Goldbourt,et al.  ASSOCIATIONS OF SERUM HIGH DENSITY LIPOPROTEIN AND TOTAL CHOLESTEROL WITH TOTAL, CARDIOVASCULAR, AND CANCER MORTALITY IN A 7-YEAR PROSPECTIVE STUDY OF 10 000 MEN , 1981, The Lancet.